Global calcium channel blockers Market Set to grow as Demand for Hypertension Treatments Rises
Apr 29
<p>The global calcium channel blockers market was valued at USD 14.5 billion in 2022 and is projected to surpass USD 24.0 billion by the end of 2031, growing at a CAGR of 5.7% from 2023 to 2031. This growth is driven by the rising prevalence of cardiovascular diseases, increasing geriatric population, and growing demand for effective hypertension and heart disorder treatments, alongside ongoing advancements in pharmaceutical formulations and drug accessibility.</p><p>Increase in prevalence of cardiovascular diseases, surge in geriatric population, and rise in availability of combination therapies are driving the global calcium channel blockers market. Development of newer formulations and increase in healthcare expenditure are expected to bolster market growth. Furthermore, rise in awareness among healthcare professionals and patients about the benefits of calcium channel blockers (CCBs) are propelling global calcium channel blockers market size.</p><p><strong>Dive Deeper into Data: Get Your In-Depth Sample Now! <a href="https://www.transparencymarketresearch.com/sample/sample.php?flag=S&amp;rep_id=35687">https://www.transparencymarketresearch.com/sample/sample.php?flag=S&amp;rep_id=35687</a> </strong></p><p>Increase in adoption of combination therapies and development of newer formulations of CCBs with improved pharmacokinetic properties and fewer side effects offer lucrative opportunities to market players. Companies are focusing on development of customized CCBs that can be tailored to individual patients' needs. Rise of telemedicine and remote patient monitoring is expected to increase access to CCBs and improve patient outcomes.</p><p><strong>Key Findings of the Market Report</strong></p><ul><li>Based on drug class, <strong>Dihydropyridines</strong> (e.g., Amlodipine, Nifedipine) lead by a wide margin, while <strong>Phenylalkylamines</strong> (e.g., Verapamil) maintain a steady niche for arrhythmia and cluster headache management.</li><li><strong>Hypertension</strong> is the dominant disease indication, accounting for <strong>48% to 54.2%</strong> of global revenue in 2026.</li><li><strong>Hospital Pharmacies</strong> remain the primary distribution channel (<strong>42% share</strong>), supported by bulk institutional procurement for acute cardiovascular care.</li><li><strong>Geriatric populations</strong> (65+) represent the primary consumer base, as aging is intrinsically linked to increased arterial stiffness and isolated systolic hypertension.</li></ul><p><strong>Global Market: Growth Drivers</strong></p><ul><li><strong>Escalating Global Hypertension Burden:</strong> With billions of individuals affected worldwide, the "silent killer" remains the primary volume driver for CCB prescriptions.</li><li><strong>Advancements in FDC Combinations:</strong> Fixed-dose combinations with ACE inhibitors or diuretics are improving patient compliance and clinical outcomes.</li><li><strong>Rapid Urbanization in APAC:</strong> Shifts toward sedentary lifestyles and dietary changes in emerging economies are creating millions of new hypertension cases annually.</li><li><strong>Aging Global Demographic:</strong> The increase in the number of elderly people is driving sustained demand for long-term chronic disease management therapies.</li></ul><p><strong>Global Market: Key Players</strong></p><p>Industry leadership is divided between "innovator" firms focusing on high-value FDCs and "generic titans" specializing in high-volume, low-cost production.</p><ul><li><strong>Pfizer Inc. (Market Leader - Norvasc)</strong></li><li><strong>Novartis AG (Exforge)</strong></li><li><strong>GlaxoSmithKline Plc</strong></li><li><strong>Bausch Health Companies Inc.</strong></li><li><strong>Teva Pharmaceutical Industries Ltd.</strong></li><li><strong>Sun Pharmaceutical Industries Ltd.</strong></li><li><strong>Mylan N.V. (Viatris)</strong></li><li><strong>Lupin Limited</strong></li><li><strong>AstraZeneca plc</strong></li><li><strong>Zydus Lifesciences</strong></li></ul><p><strong>Global Market: Segmentation</strong></p><p><strong>By Drug Class</strong></p><ul><li>Dihydropyridine (Amlodipine, Nifedipine) - Market Leader</li><li>Benzothiazepine (Diltiazem)</li><li>Phenylalkylamine (Verapamil)</li></ul><p><strong>By Disease Indication</strong></p><ul><li>Hypertension (Primary Driver)</li><li>Chest Pain (Angina Pectoris)</li><li>Arrhythmias</li><li>Others (Coronary Artery Disease, Hypertrophic Cardiomyopathy)</li></ul><p><strong>By Distribution Channel</strong></p><ul><li>Hospital Pharmacy (Institutionally Dominant)</li><li>Retail Pharmacy</li><li>Online Pharmacy (Fastest Growth)</li></ul><p><strong>Buy this Premium Research Report: <a href="https://www.transparencymarketresearch.com/checkout.php?rep_id=35687&amp;ltype=S">https://www.transparencymarketresearch.com/checkout.php?rep_id=35687&amp;ltype=S</a> </strong></p><p><strong>About Transparency Market Research</strong></p><p><strong>Transparency Market Research</strong>, a global <a href="https://www.globenewswire.com/Tracker?data=MKyRdE0P94ioyU9f_0pp_wK0uV5-pktG40_qdemb39yORO5ij1UiDsjS3kZVPgI-OU0u348INknIe5Axs0iEQkizjjMb2WGH24rFxKRmG66df6VI3JqcmmcboAodjufF"><strong>market research company</strong></a> registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.</p><p>Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.</p><p><strong>Contact:</strong></p><p><strong>Abhishek Budholiya<br />Transparency Market Research Inc.<br /></strong>State Tower, 90 State Street, Suite 700,<br />Albany NY - 12207, United States<strong><br />Tel: </strong>+1-518-618-1030<br /><strong>USA – Canada Toll Free: </strong>866-552-3453<strong><br />Website: </strong><a href="https://www.transparencymarketresearch.com"><strong>https://www.transparencymarketresearch.com</strong></a><strong> <br />Sales Inquiries: sales@transparencymarketresearch.com<br />Media Inquiries: </strong><a href="mailto:media@transparencymarketresearch.com"><strong>media@transparencymarketresearch.com</strong></a></p>